Related by context. All words. (Click for frequent words.) 66 CRx 64 NLX P# 63 INGN 63 decitabine 63 Bezielle 62 MYDICAR ® 62 brivaracetam 62 Cotara 62 BAY #-# 62 ProSavin 62 Traficet EN 62 Sym# 62 orally bioavailable 62 Phase 2a trial 61 AAV2 61 TG# [003] 61 CIMZIA TM 61 ataluren 61 PSMA ADC 61 ISIS # 61 CIMZIA ™ 60 Spheramine 60 IFN alfa 60 tafamidis 60 octreotide 60 MORAb 60 riociguat 60 DAPT 60 Azedra 60 autologous bone marrow 60 phase IIa clinical 60 INT# [002] 60 PROCHYMAL 60 GRN# 60 antisense drug 59 huN# DM1 59 rindopepimut 59 CCX# 59 recurrent glioblastoma multiforme 59 INCB# [001] 59 MGd 59 OZURDEX ® 59 phase IIb clinical 59 MT# MEDI 59 Phase 2a clinical 59 JVRS 59 GAMMAGARD 59 XmAb# 59 SGS# 59 omega interferon 59 CA4P 59 methylnaltrexone 59 HQK 59 telaprevir VX 59 PRX# 59 SRT# [003] 59 dosing cohorts 59 VBLOC Therapy 59 CRLX# 59 cortical stimulation 59 Preclinical studies 59 RG# [001] 59 forodesine 59 alagebrium 59 PRTX 59 ANG# 59 liposomal formulation 59 PROMACTA 58 Enkephalin 58 IFN α 58 IPL# 58 neurotrophic factor 58 DACH platinum 58 AEZS 58 HCV protease inhibitor 58 R#/MEM # 58 preclinical efficacy 58 inhibitor RG# 58 AAV vector 58 HGS ETR1 58 CR# vcMMAE 58 HuMax CD4 58 Symadex 58 pitavastatin 58 placebo controlled Phase 58 Debio 58 placebo controlled clinical 58 NTDDS 58 VQD 58 Pimavanserin 58 YONDELIS 58 MEK inhibitor 58 AEG# 58 multicenter Phase 58 RhuDex ® 58 Oral NKTR 58 OncoVEX GM CSF 58 EQUIP OB 58 EndoTAG TM -1 58 huC# DM4 58 metreleptin 58 polymerase inhibitor 58 histone deacetylase HDAC inhibitor 58 favorable pharmacokinetic profile 58 enzastaurin 58 TRO# 58 EchoCRT 58 alemtuzumab Campath 58 daclizumab 58 PARP inhibitor 58 Cethrin 58 sd rxRNA compounds 58 administered subcutaneously 58 PEG SN# 58 IMA# 58 Phase Ib study 58 FTY# 58 ZYBRESTAT 58 APTIVUS r 58 tarenflurbil 57 subcutaneous PRO 57 Phase 2b study 57 davunetide intranasal AL 57 ELND# 57 double blinded placebo 57 tremelimumab 57 ORMD 57 axitinib 57 metastatic RCC 57 tumor specific antigen 57 PF # [001] 57 mertansine 57 Microplasmin 57 relapsing remitting multiple sclerosis 57 GVAX 57 elacytarabine 57 RRMS patients 57 castration resistant prostate cancer 57 orally dosed 57 bendamustine 57 Phase 2b trial 57 cannabinor 57 Lixivaptan 57 Amrubicin 57 RVX 57 GPNMB 57 ATL# [001] 57 PD LID 57 pharmacodynamics 57 subcutaneously administered 57 oral FTY# 57 GRNOPC1 cells 57 Phase Ib clinical 57 chlorambucil 57 ZFP TF 57 mapatumumab 57 Phase IIa trial 57 Phase IIa trials 57 Factor VIIa 57 amrubicin 57 relapsing multiple sclerosis 57 LY# [003] 57 lung metastases 57 PXD# 57 siRNA therapeutic 57 ACZ# 57 phase IIb study 57 HGS# 57 CD# antibody [001] 57 ESBA# 57 MNTX 57 ThGRF 57 VA# [002] 57 sd rxRNA 57 metaglidasen 57 PRT# 57 IMC A# 57 cilengitide 57 pharmacodynamic profile 57 OncoVEX 57 PEG Interferon lambda 57 VEGF receptor 57 phase IIb trial 57 EZN 57 preclinically 57 TTF Therapy 57 leukemia AML 56 EDEMA3 56 JAK inhibitor 56 Daclizumab 56 ZOLINZA 56 angiogenesis inhibitor 56 CINTREDEKIN BESUDOTOX 56 Mipomersen 56 dexpramipexole 56 vidofludimus 56 PEGylated Fab fragment 56 GRNVAC1 56 darapladib 56 Resten NG 56 CTAP# Capsules 56 mcg albinterferon alfa 2b 56 VAPRISOL 56 SNT MC# 56 ISF# 56 4SC 56 PAOD 56 pomalidomide 56 pharmacokinetic PK study 56 mutated KRAS 56 EGFRvIII 56 treatment naïve genotype 56 nucleoside analog 56 CANCIDAS 56 pegylated liposomal doxorubicin 56 ARRY 56 MAGE A3 ASCI 56 MYDICAR 56 Cogane 56 Retisert 56 Litx 56 lumiliximab 56 Gleevec resistant 56 immunomodulatory therapy 56 recurrent glioma 56 CBLC# 56 fosbretabulin 56 Revascor TM 56 anti CD3 antibody 56 CDK inhibitor 56 HuMax CD# 56 NKTR 56 Aflibercept 56 metastatic hormone refractory 56 OHR/AVR# 56 Phase IIB 56 Phase #b/#a trial 56 Phase IIa clinical 56 Phase IIb trials 56 thymalfasin 56 Tyrima 56 CTCE 56 tanespimycin 56 Laquinimod 56 BRIM2 56 ADXS# 56 GSK# [001] 56 IMGN# 56 HCV SPRINT 56 ganetespib 56 ADAGIO study 56 somatostatin analogue 56 Triolex 56 edifoligide 56 Alocrest 56 otelixizumab 56 CoFactor 56 INCB# [002] 56 Tamibarotene 56 MultiStem 56 Xanafide 56 visilizumab 56 alvespimycin 56 dose escalation phase 56 dose cohort 56 alemtuzumab treated 56 neurotrophic factors 56 SNT-MC#/idebenone 56 humanized monoclonal antibody 56 IAP inhibitor 56 histone deacetylase inhibitor 56 somatostatin analog 56 Natalizumab 56 CEQ# 56 ARIKACE 56 TRIOLEX 56 multicenter Phase II 56 Ataluren 55 ADVANCE PD 55 synthetic retinoid 55 Enzastaurin 55 TNFa 55 EGb 55 TroVax ® 55 sipuleucel T 55 Vernakalant 55 Cethromycin 55 Pradefovir 55 IRX 2 55 vorinostat 55 recombinant adeno associated 55 durable remissions 55 TYSABRI natalizumab 55 HCV NS5B polymerase 55 abiraterone acetate 55 nab paclitaxel 55 APTIVUS 55 remyelination 55 microRNA miR 55 fenretinide 55 AEGR 55 PTC# 55 Neurodex 55 survivin 55 ximelagatran 55 Reverset 55 blinded randomized 55 beta 1a 55 INGAP 55 IGFBP 3 55 EVIZON 55 ularitide 55 viral kinetic 55 CYT# 55 K ras mutations 55 selective inhibition 55 LEUKINE 55 imetelstat 55 dosing cohort 55 antibody MAb 55 refractory CLL 55 Ceplene/IL-2 55 ABSORB trial 55 LT NS# 55 Hepatocellular Carcinoma HCC 55 laquinimod 55 colorectal liver metastases 55 relapsed multiple myeloma 55 chemoradiotherapy 55 GHRH 55 OXi# 55 oligodendrocyte progenitor cells 55 PDE4 inhibitor 55 MET amplification 55 Phase Ib 55 trabedersen 55 EFAPROXYN 55 aerosolized KL4 surfactant 55 rilonacept 55 sporadic ALS 55 canakinumab 55 flavopiridol 55 pancreatic adenocarcinoma 55 carboplatin paclitaxel 55 ruboxistaurin 55 IV NSCLC 55 DEB# 55 TREANDA 55 Actilon 55 Inhaled nitric oxide 55 GW# [003] 55 pertuzumab 55 volociximab 55 CGEN # 55 controlled multicenter Phase 55 Vivaglobin 55 radiolabeled 55 nitazoxanide 55 Androxal TM 55 Aptivus ® 55 elotuzumab 55 mTOR inhibitors 55 antithrombotic 55 MKC# MKC# PP 55 gefitinib Iressa 55 denufosol 55 liver metastases 55 ONTAK 55 Amplimexon 55 FVIIa 55 nutlin 55 gemcitabine cisplatin 55 OncoGel 55 ELACYT 55 GRNCM1 55 Phase Ia 55 interferon beta 1b 55 diabetic nephropathy 55 progressive neurodegenerative disorder 55 trial evaluating PRX# 55 IIa trial 55 adenoviral 55 INC# 55 CUDC 55 seliciclib 55 EOquin 55 IMC #B 55 KNS # 55 gemcitabine carboplatin 55 BNC# 55 Elocalcitol 55 μg dose 55 Insegia 55 JAK3 55 AAG geldanamycin analog 55 EOquin TM 55 GDNF 55 DDP# 55 Diabetic Macular Edema 55 NTx TM -# 55 indibulin 55 pDCs 55 oral ridaforolimus 55 humanized antibody 55 Kahalalide F 55 Gliadel Wafer 55 GBM tumors 55 Rebif ® 55 Posiphen 55 budesonide foam 55 obatoclax 55 adeno associated virus 55 Virulizin ® 55 Vectibix monotherapy 55 LHRH receptor 55 treatment naive genotype 55 Nanobody 54 GGF2 54 fibrotic disease 54 anti amnesic 54 HCV protease inhibitors 54 collagenase 54 AVONEX ® 54 mg/m2 dose 54 Trastuzumab 54 regorafenib 54 Vandetanib 54 diabetic neuropathic pain 54 Plicera 54 Phase IIb trial 54 OMP #R# 54 LCP Tacro 54 clinical pharmacology studies 54 evaluable subjects 54 ULORIC 54 generation antisense 54 CCR5 mAb 54 recurrent NSCLC 54 PLX# 54 XIENCE V stent 54 OMS# 54 Proxinium TM 54 exon skipping 54 synthetic peptide 54 selective agonist 54 relapsed refractory multiple myeloma 54 underwent surgical resection 54 TELINTRA 54 gastrointestinal stromal tumors 54 BCIRG 54 targeted radiotherapeutic 54 mGluR5 antagonist 54 Ecallantide 54 SUVN 54 sargramostim 54 Guanilib 54 Pharmacokinetics PK 54 IDH1 54 dexanabinol 54 metastatic renal cell carcinoma 54 dose escalation Phase 54 Fibrillex TM 54 Golimumab 54 ATL/TV# 54 lentiviral vector 54 Ostarine 54 colorectal cancer liver metastases 54 trastuzumab Herceptin 54 AQ4N 54 histone deacetylase inhibitors 54 PRX # 54 PS# [001] 54 inhaled treprostinil 54 darunavir ritonavir 54 DCVax ® Brain 54 intravenous dosing 54 familial ALS 54 chemoresistant 54 inhibit metastasis 54 Vascugel 54 pCR 54 cleavable linker 54 vascular disrupting agent 54 olmesartan 54 FLT3 54 CCR5 antagonist 54 BrachySil TM 54 nonclinical studies 54 ACV1 54 poloxamer 54 syngeneic 54 SUTENT 54 Alemtuzumab 54 KRAS mutations occur 54 comparator arm 54 Genz # 54 uPA 54 COU AA 54 INCB# [003] 54 standard chemotherapy regimen 54 ProMune 54 double blinded randomized 54 PROSTVAC TM 54 everolimus eluting stents 54 TTR gene 54 Phase #/#a 54 DermaVir Patch 54 evaluable patients 54 antisense oligonucleotide 54 2DG 54 sitaxsentan 54 Neulasta ® 54 NCCTG 54 PKCi 54 Seliciclib 54 AGGRASTAT R 54 Dacogen injection 54 masitinib 54 SERCA2a 54 CIMZIA TM certolizumab pegol 54 analgesic efficacy 54 octreotide implant 54 DU #b 54 HGS ETR2 54 Omacetaxine 54 rhIL 7 54 lanreotide 54 Doxil ® 54 myoblast therapy 54 AAV vectors 54 TELCYTA 54 eltrombopag 54 ReN# 54 Gefitinib 54 PLX cells 54 ImmunoVEX HSV2 54 Viprinex 54 mitoxantrone 54 RAPAFLO 54 initiate Phase 1b 54 neoadjuvant chemotherapy 54 Chemophase 54 Nanobodies ® 54 SOD1 gene 54 endostatin 54 Cethrin R 54 P#X# 54 ibudilast 54 novel VDA molecule 54 intra arterial 54 Phase 1a 54 rALLy clinical trial 54 Filgrastim 54 abiraterone 54 INTEGRILIN 54 Gabapentin GR 54 tramiprosate 54 Tavocept 54 mineralocorticoid receptor 54 TACI Ig 54 docetaxel chemotherapy 54 Ranibizumab 54 Allovectin 7 R 54 Curaxin CBLC# 54 Neupogen ® 54 recurrent GBM 54 dose escalation clinical 54 elvucitabine 54 nonsmall cell lung cancer 54 viral kinetics 54 Campath alemtuzumab 54 CCX# B 54 Imprime PGG 54 DFMO 54 LUX Lung 54 anti EGFR antibody 54 weekly intravenous infusions 54 HCV infected 54 multicenter randomized placebo controlled 54 chemokine receptor 54 HER2/neu 54 BRIM3 54 muraglitazar 54 Anavex #-# 54 tesmilifene 54 rBChE 54 Cetrorelix 54 neuroblastoma tumors 54 ROCKET AF 54 thrombocytopenic patients 54 CHAMPION PCI 54 Pharmacokinetic studies 54 mcg doses 54 nucleotide analog 54 crizotinib PF # 54 vandetanib 54 cinacalcet 54 XL# SAR# 54 lomitapide 54 CGRP 54 TYKERB 54 Aloxi injection 54 PEGylated 54 TRC# 54 Torisel 54 orally administered inhibitor 54 Prodarsan ® 53 Glypromate 53 cyclosporin 53 SOD1 53 PREZISTA r 53 CCR9 antagonist 53 receptor agonist 53 relapsed CLL 53 TYZEKA 53 insulin detemir 53 TBC# 53 RG# ITMN 53 Zolinza 53 metastatic renal cell 53 medullary thyroid cancer 53 pharmacokinetic PK profile 53 BiTE 53 Bortezomib 53 Inhaled AAT 53 NeuVax 53 BRAF inhibitor 53 NATRECOR R 53 solithromycin 53 Ocrelizumab 53 iniparib 53 Thrombin 53 Desmoteplase 53 DAVANAT 53 bispecific antibody 53 chemotherapeutic drug 53 dasatinib Sprycel 53 malignant pleural mesothelioma 53 Atrasentan 53 diabetic macular edema 53 pharmacokinetic PK 53 RhuDex R 53 phase III ACCLAIM 53 pharmacodynamic PD 53 DUROS 53 preclinical studies 53 IMP# 53 cediranib 53 PrevOnco 53 Cerashield 53 Medidur FA 53 superficial bladder cancer 53 olaparib 53 Synavive 53 VELCADE melphalan 53 Ophena TM 53 PSN# [002] 53 paclitaxel poliglumex 53 IRESSA 53 MoxDuo 53 patients evaluable 53 plasma kallikrein inhibitor 53 randomized controlled Phase 53 azilsartan medoxomil 53 atacicept 53 SYN# 53 phase IIb 53 AGGRASTAT ® 53 CCR2 53 RSD# oral 53 GLPG# 53 dose limiting toxicities 53 posaconazole 53 Abbokinase 53 Anticalin R 53 farletuzumab 53 confirmatory Phase III 53 novel peptide 53 Allovectin 7 ® 53 PEG PAL 53 randomized Phase IIb 53 IL# PE#QQR 53 vinorelbine 53 neurotrophic 53 Randomized Phase 53 Pertuzumab 53 CALGB 53 trabectedin 53 Capesaris 53 Irinotecan 53 Fc fusion protein 53 follicular lymphomas 53 gene therapy 53 afatinib 53 selective androgen receptor modulator 53 mRCC 53 Phase 1b clinical 53 NSCLC tumors 53 Phase IIb clinical trials 53 G CSF 53 immunostimulatory 53 Ophena 53 low dose cytarabine 53 Nuvion 53 investigational compounds 53 muscarinic 53 Civacir 53 INNO 53 DXL# 53 Phase #/#a trial 53 panitumumab 53 miglustat 53 Liposomal 53 oral ghrelin agonist 53 pro angiogenic 53 Xcellerated T Cells 53 RLY# 53 ALN TTR# 53 rFVIIIFc 53 biliary tract cancer 53 adult chronic ITP 53 chemoradiation therapy 53 minocycline 53 glioblastoma tumors 53 tinzaparin 53 TIMP 1 53 PEG IFN 53 Rexin G 53 antitumor 53 CIPN 53 relapsed AML 53 Rasagiline 53 Cysteamine 53 depsipeptide 53 targeting CD# 53 Lisofylline 53 telomerase activation 53 Dabigatran etexilate 53 HCD# [002] 53 calcineurin inhibitors 53 ritonavir boosted 53 MyoCell 53 erlotinib Tarceva ® 53 pancreatic neuroendocrine tumors 53 NOX E# 53 proteasome inhibitor 53 Neuvenge 53 entinostat 53 PI3K inhibitor 53 pancreatic islet cell 53 Multimeric 53 Cimzia ® certolizumab pegol 53 sunitinib malate 53 nonsense mutation 53 complete cytogenetic response 53 Phase Ib II 53 lenalidomide Revlimid R 53 concurrent chemoradiation 53 oncolytic virus 53 hyperphenylalaninemia HPA due 53 metastatic HRPC 53 locoregional disease 53 zalutumumab 53 PDE# inhibitors 53 peginterferon alfa 2a 53 Ceflatonin 53 Zyclara 53 fluoropyrimidine 53 GV# [001] 53 rFSH 53 Everolimus 53 #beta HSD1 53 gamma secretase inhibitor 53 alpha folate receptor 53 custirsen 53 Leber congenital amaurosis 53 sodium glucose cotransporter 53 Azilect ® 53 IV Busulfex 53 PPAR gamma agonist 53 ER CHOP 53 cisplatin chemotherapy 53 PHX# 53 secretin 53 5FU 53 zanolimumab 53 PNP inhibitor 53 Nexavar sorafenib 53 Phase 1b clinical trials 53 subconjunctival injection 53 mCRC patients 53 Amigal 53 vismodegib 53 refractory acute myeloid 53 Phase IIIb clinical 53 Phase III randomized controlled 53 virus AAV 53 pradefovir 53 potent antiproliferative 53 NexACT 53 HCV RESPOND 2 53 GAP #B# 53 E1 INT TM 53 HER2 positive metastatic breast 53 antiangiogenic therapy 53 randomized multicenter 53 Diamyd ® 53 rituximab Rituxan 53 Catena ® 53 midstage clinical 53 romidepsin 53 ARCALYST ® rilonacept 53 Vicinium TM 53 NN# [001] 52 therapeutic monoclonal antibody 52 heavily pretreated patients 52 BRAF mutation 52 JAK1 52 cell lymphoma CTCL 52 RNAi therapeutic targeting 52 Ceregene 52 cidofovir 52 blinded placebo controlled 52 docetaxel Taxotere ® 52 phase Ib 52 RPE# 52 Phase #b/#a 52 Aurexis 52 Phase 1a clinical 52 Arch Surg 52 CALGB # [002] 52 hedgehog pathway 52 bevacizumab Avastin ® 52 Phase #b/#a clinical 52 Intravenous CP 52 sunitinib 52 LRAT 52 axonal regeneration 52 T2DM 52 Cloretazine R VNP#M 52 histone deacetylase HDAC 52 omacetaxine mepesuccinate 52 Sapacitabine 52 ibandronate 52 telaprevir dosed 52 HSP# inhibitor 52 Alzhemed TM 52 Zilver PTX stent 52 BiovaxID 52 Vascugel ® 52 KRN# 52 Uricase PEG 52 mda 7 52 protease inhibitor PI 52 ToGA 52 CD# monoclonal antibody 52 Bicifadine 52 T#M mutation 52 acute PAO 52 DP b# 52 HuLuc# 52 ruxolitinib 52 colorectal carcinoma 52 CYT# potent vascular disrupting 52 IDH1 mutation 52 MVax 52 underwent liver transplantation 52 Granulocyte Colony Stimulating Factor 52 venlafaxine XR 52 KRAS wild 52 immunoconjugate 52 intravenously administered 52 RAV# 52 renal tumors 52 β2 52 LHON 52 Tanespimycin 52 Tarvacin 52 carcinoid 52 Asentar 52 PrevOnco ™ 52 Olaparib 52 RGB # 52 Dacogen decitabine 52 paricalcitol 52 Wnt signaling 52 HORIZONS AMI trial 52 neuroprotection 52 nonmyeloablative 52 peg interferon 52 Myelodysplastic Syndrome MDS 52 Anthim 52 metastatic neuroendocrine tumors 52 WT1 52 T#I mutation 52 fostamatinib 52 anti angiogenic therapy 52 Vitaxin 52 SparVax TM 52 Tesmilifene 52 oncolytic vaccine 52 multiple ascending dose 52 VitiGam 52 metastatic lung cancer 52 BRAF V#E mutation 52 Janus kinase 52 IMPACT DCM clinical 52 EGF receptor 52 Zirgan 52 T#I [002] 52 relapsing remitting 52 OMNARIS Nasal Spray 52 TMC# C# 52 RE LY ® 52 A1PI 52 taxane chemotherapy 52 Myelodysplastic syndromes MDS 52 TOCOSOL Paclitaxel 52 LB# [003] 52 Islet transplantation 52 EndoTAG 52 iSONEP 52 talactoferrin 52 basiliximab 52 ZYBRESTAT fosbretabulin 52 GFT# 52 NRG1 52 ADP receptor antagonist 52 multicenter randomized controlled 52 BIBW 52 neural cells 52 recurrent glioblastoma 52 GRASPA ® 52 edoxaban 52 tipifarnib 52 enzyme inhibitor 52 belinostat 52 ApoE4 52 #I TM# 52 Fenretinide 52 aflibercept 52 APOPTONE 52 Ascendra 52 Tβ4 52 VEGF Trap 52 tumor antigen 52 anakinra 52 Phase IIA 52 HspE7 52 Octreolin 52 #D#C# 52 registrational clinical 52 radezolid 52 phase IIa 52 stage IIIb IV 52 TroVax 52 prostate cancer AIPC 52 achieved CCyR 52 stage IIIB 52 metastatic CRC 52 AKT inhibitor 52 pharmacological chaperone 52 HuMax EGFr 52 glufosfamide 52 anticancer compound 52 cMET 52 Indaflex TM 52 lesinurad 52 metastatic melanomas 52 selective antagonist 52 ALN HPN 52 ribavirin RBV 52 multicenter clinical 52 Pervasis 52 Interferon alfa 52 miR #a [002] 52 tipranavir 52 AIR2 Trial 52 TLR9 agonist 52 Glufosfamide 52 Firazyr 52 AA amyloidosis 52 PKC# 52 galiximab 52 NTx 52 radiolabeled monoclonal antibody 52 docetaxel Taxotere R 52 controlled multicenter 52 symptomatic BPH 52 everolimus eluting stent 52 Ceflatonin R 52 viral vector 52 Belerofon 52 evaluable 52 gefitinib 52 Naive Patients 52 oral antiviral 52 cabazitaxel 52 hematological cancers